HOME >> BIOLOGY >> NEWS
Mouse model reveals that oncoprotein induces abnormal preleukemic blood cell progenitors

Scientists have developed a novel mouse model for leukemia that reveals critical information about the mechanisms involved in leukemia progression and provides a model system for evaluation of new drugs for treatment of leukemia. The research, published in the January issue of Cancer Cell, utilizes a technique that allows induction and study of a key oncoprotein in adult mice. Previously, it was difficult to investigate this oncoprotein in the mouse, as the expression of this gene is associated with embryonic lethality, or death of the developing mouse in utero.

Acute myeloid leukemia (AML) can arise from genetic alterations in the bone marrow cells that give rise to blood cells. One fusion oncoprotein that is present in about 12% of human AML cases and is known to interfere with the process of normal blood cell development is called CBFB-SMMHC. Thus far, this protein has been very difficult to study in mouse models, as its expression causes embryonic lethality. Dr. Lucio H. Castilla from the Program in Gene Function and Expression at the University of Massachusetts Medical School and colleagues created a conditional mouse model to analyze the preleukemic effects of CBFB-SMMHC on blood cell production and AML development in adult mice. The mouse model enabled the scientists to selectively turn on expression of CBFB-SMMHC in adult mice, thereby avoiding embryonic lethality of expression of this gene, and then study the effects.

The researchers found that CBFB-SMMHC induction was associated with a reduction of immature blood cells in the bone marrow and with the appearance of abnormal progenitor cells that are leukemic precursors. Mice expressing CBFB-SMMHC developed AML with a median latency of approximately five months, with the time of disease onset varying with the number of abnormal cells in the bone marrow. Interestingly, additional studies showed that the blood stem cell precursors that expressed CBFB-SMMHC were maintained at normal levels for l
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
17-Jan-2006


Page: 1 2

Related biology news :

1. Mouse model advances understanding of synovial sarcoma
2. Mouse FH knockout resembles human renal cell cancer
3. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
4. Mouse model underestimates the critical role of Tyk2 in human immune system
5. Mouse DNA to aid biomedical research
6. Mouse strain with gene stutter will help leukemia research
7. Knockout Mouse Project
8. NIH launches Knockout Mouse Project
9. Mouse mimics chronic leukemia, will aid drug development
10. Mouse, frog and bird put Snail and Slug to different uses
11. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk

Post Your Comments:
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:8/31/2015)... , Aug. 31, 2015  For people with Down ... their day. The biotechnology company, located in the Science ... of the best potential therapies yet for people with Down ... " Correction of Down syndrome and Edwards syndrome aneuploidies ... DNA Research . Elixirgen plans to develop this ...
(Date:8/31/2015)... 31, 2015 FLX Bio, Inc., a biopharmaceutical ... cancer immunotherapies, announced today that it has appointed ... and William Ho , M.D., Ph.D., as Chief ... management team led by veterans of Flexus Biosciences, Inc., ... Scientific Officer; Jay Powers , Ph.D., Vice President, ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive menstrual ... available new FDA approved system in the last 14 years, and the only endometrial ... (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... presented two studies at the International Spine Intervention Society’ s 23rd ... through to August 1st, 2015. With a focus on evidence-based research and clinical ...
Breaking Biology Technology:New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
Cached News: